

Recommendation	Subscribe	
Price Band	Rs 28-30	
Bidding Date	05th – 07th Nov, 2024	
Book Running Lead Manager	ICIC Sec, IIFL sec, Jefferies Ind Ltd, J.P Morgan	
Registrar	Link Intime India Private Limited	
Sector	IT	
Minimum Retail Application- Detail At Cut off Price		
Number of Shares	500	
Minimum Application Money	Rs. 15000	
Discount to retail	0	
Payment Mode	ASBA	
Consolidated Financials (Rs Cr)	FY23	FY24
Total Income	4,218	4,754
Adj EBITDA	1045	1171
Adj PAT	456	590
Valuations (FY24)	Lower Band	Upper Band
Market Cap (Rs Cr)	13,108	14,044
Adj EPS	0.97	1.26
PE	29	24
EV/ EBITDA	15	13
Enterprise Value (Rs Cr)	14,697	15633
Post Issue Shareholding Pattern		
Promoters	85.0%	
Public/Other	15.0%	
Offer structure for different categories		
QIB (Including Mutual Fund)	75%	
Non-Institutional	10%	
Retail	15%	
Post Issue Equity (Rs. in cr)	4681.3	
Issue Size (Rs in cr)	2106	
Face Value (Rs)	10	
Kavita S Vempalli Research Analyst (+91 22 6273 8034) kavita.vempalli@nirmalbang.com		

BACKGROUND

Sagility is a pure healthcare focused technology driven service provider having client profile of **Payers** which include leading U.S. health insurance companies and **Providers** including hospitals, physicians, and diagnostic and medical devices Company's amongst others. 90% of the company's revenues come from the payers segment where it is involved in the core benefit admin functions deriving predictable revenues. It operates through five global service delivery locations present in India, the Philippines, the U.S., Jamaica and Colombia.

Sagility holds deep domain expertise and leadership position in the focused payer healthcare market offering comprehensive services as against the other traditional IT players. With growing outsourcing outlook of the traditionally conservative Healthcare industry, Sagility holds a better position to gain traction and gain market share. Shares are available at an adjusted P/E of 24x and EV/EBIDTA of 13x FY24 earnings which seems reasonable given its highly focused nature of business and thus recommend '**Subscribe**' to the issue.

Details of the Issue:

IPO is a book-building issue worth Rs. 2,106.6 crore comprising only an offer-for-sale (OFS) of 70.22 crore shares.

Objects of the Issue:

To list on the stock exchange.

Investment Rationale:

1. Leader in large US Healthcare Payer and Provide Market.
2. Deep Domain Expertise enabling end to end service offerings.
3. Strategic Advantages with strong Promoter background.
4. Stable and Good Financial Performance with good set of margins.


Financials	FY23	FY24	Q1FY25
Net Revenues	4,218	4,754	1,223
Growth (%)	-	12.7%	9.6%
EBITDA	1,027	1,088	194
EBITDA Margin (%)	24.4%	22.9%	15.9%
Adjusted EBITDA	1044.86	1171.46	315.97
PBT	186	242	71
Adjusted PAT	456	590	145
EPS	0.97	1.26	0.31
ROE	7.3%	9.2%	7.6%
ROCE	4.7%	5.1%	5.1%
EV/Sales	3.7	3.3	3.2
Adj EV/EBITDA	15.0	13.3	12.4
Adj P/E	30.8	23.8	24.3

Company Background

Sagility (earlier part of Hinduja Global Ltd) is a pure healthcare focused technology driven service provider having client profile of **Payers** which include leading U.S. health insurance companies and **Providers** including hospitals, physicians, and diagnostic and medical devices co's amongst others. It provides services to Payers with respect to various aspects of their operations including (i) **core benefits** admin functions such as claims management, enrolment, benefits plan building, premium billing, credentialing, and provider data management and (ii) **clinical functions** such as utilization management, care management, and population health management. For Providers, Co offers services which include revenue cycle management such as financial clearance, medical coding, billing, and accounts receivable follow-up services. Cooperates through five global service delivery locations in India, the Philippines, the U.S., Jamaica and Colombia.

Payer services

- **Claims Management**
 - They manage the claims settlement process for Payers, which includes reviewing and validating claims from Providers to ensure alignment with the Member's benefits plan and Provider contracts. This process ensures that claims are processed accurately and paid promptly.
- **Payment Integrity**
 - Payers control costs by identifying claim overpayments and ensuring that the correct amounts are paid for claims submitted by healthcare Providers.
- **Clinical Management**
 - Their clinical management services focus on delivering timely, high-quality care for Members, supporting Payers in managing healthcare costs while ensuring that Members receive necessary and appropriate care from Providers.
- **Other Payer services**
 - They also assist Payers with onboarding new Providers to their networks and managing Provider databases. The onboarding process includes verifying credentials and maintaining an accurate Provider directory within a Payer's network, which is a regulatory requirement in the U.S.



Note: DIME: Durable Medical Equipment. 1. For FY2024.


Source: Company, NBRR

Provider Services

- **Revenue Cycle Management (RCM)**
 - They are all-inclusive RCM (Revenue Cycle Management) service provider, offering scheduling and financial clearance services to Providers, including insurance verification, benefits validation, referral management, and prior authorizations. They also support Providers with order entry, charge entry, and medical coding. For revenue cycle services, they provide billing and follow-up focused on collecting and resolving insurance and patient balances.

Industry overview


Healthcare is an intricate segment of the US economy accounting for 17.1% of its nominal GDP and amounting to US\$4.7 tn (₹389.6 tn) in 2023 as per the latest projections by Centers for Medicare & Medicaid Services (“CMS”). This expenditure has grown at a CAGR of 5.0% from 2014 to 2023. The healthcare expenditure surged to 19.4% of the nominal GDP in 2020 during COVID-19, totaling US\$ 4.1 tn (₹ 346.0 tn).



Source: Everest Report

The US healthcare market comprises of two primary entities with respect to care financing and care delivery – healthcare payers and healthcare providers:

- Healthcare payers:** Healthcare payers are entities that pay for or reimburse healthcare services for insured members through health insurance plans.
- Healthcare providers:** Healthcare providers are individuals or healthcare facilities that are licensed to deliver care services or aid in care delivery such as doctors, clinics, hospitals, labs, durable medical equipment providers, etc.




Source: Everest Report

Investment Rationale

Leader in large US Healthcare Payer and Provide Market.

US Healthcare operations markets was estimated to be \$ 201 bn in 2023 and is expected to reach ~ \$ 259 bn in 2028. Out of this, the total outsourcing penetration rate remains at ~ 21-23% at \$ 45 bn. This market is expected to grow at a CAGR of 8.7% by 2029 as per Everest Report. Sagility has capitalized on this growing market and provides a comprehensive range of services to Payers and Providers which includes core non-discretionary benefits administration functions and clinical services. To Providers, the company provides end – to - end revenue cycle management services which help them manage their billing and payment from Payers and patients. In terms of revenues, Sagility is one of the largest healthcare specialists with coverage across payer and provider markets providing end – to - end portfolio of services in the outsourced operations market. As per Everest Report, Sagility held ~ 1.23% market share in the healthcare outsourced market.




Source: Everest Report

Company’s understanding of the complete Payer and Provider value chain helps it offer solutions that target the core administrative workflows of Payers and the revenue cycle management workflow of the Provider. Over the years, the company has developed a suite of proprietary tools and platforms that enable its services. These proprietary tools and platforms assist in serving the entire spectrum of their Payer client’s operations and also healthcare Provider client’s revenue cycle management functions.

Deep Domain Expertise enabling End to End Service Offerings

The U.S. healthcare industry is characterized by complex services, stringent compliance requirements, elaborate performance measures, and multifaceted payment workflows. These challenges necessitate the involvement of specialized service providers who possess the expertise to navigate and manage these complexities effectively.

Sagility has the domain expertise to improve the efficiency of core operations, clinical outcomes, optimize cost of care as well as modernize and digitize various functions of Payers and Providers businesses. As a specialist healthcare company, Sagility is able to assess whether treatments are “medically necessary”, predict healthcare risks based on relevant data sets, and reduce unnecessary rework in claims that result in provider abrasion and high interest payments. Company’s teams have extensive healthcare expertise and experience with ~ 1,920 employees having nursing, medical coding, physical therapy, dentistry, pharmacy, occupational therapy, microbiology or laboratory science degrees. Company successfully leverages various technologies including RPA, analytics and AI and offers end to end service offerings to its clients.



Note: LPI: Late Payment Interest, BPaaS: Business Process-as-a-Service, TAT: Turn Around Time, TPA: Third Party administrator, RCM: Revenue Cycle Management, LTC: Long Term Care.
* Includes / Excludes Tariff/Non-Tariff

Source: Everest Report

Strategic Advantages with strong Promoter background


The primary promoter of Sagility is Baring Private Equity Asia (BPEA) EQT, which acquired the healthcare business of Hinduja Global Solutions in 2021 for ~ \$1.2bn. BPEA provides Sagility with substantial financial backing enabling it to make targeted acquisitions and expand its offerings in healthcare services. This support allows the company to invest in advanced technology and acquire firms with specialized healthcare capabilities, as seen in its recent acquisition of Devlin Consulting and BirchAI.

With BPEA’s support, Sagility has scaled its operations to over 38,000 employees across five countries. This international footprint enables Sagility to tap into global healthcare markets and aid its revenue goal of reaching \$1 bn by 2026 which seems ambitious yet feasible with BPEA’s guidance. BPEA’s expertise in scaling businesses helps Sagility target large-scale clients while expanding in mid-market spaces. In summary, BPEA’s involvement offers Sagility the capital, expertise, and operational scale necessary to strengthen its position in the healthcare BPM market and meet evolving demands in healthcare management.

Stable Financial Performance with good set of margins on the backdrop of marquee clientele

Company has served five out of ten Top Payers in the US. Client retention and stickiness is also high for the company. For instance, relationship with its 3rd largest client (a national top 10 Payer) spans over 10 years. Over the years, revenues from this client have grown at a CAGR of 20.6%, consistently increase wallet share from the client.

Further, Co has also been able to add on newer clients. In 2023, 2024 the company has added 13 and 7 new clients respectively. Consequently, revenues/ adjusted EBIDTA margins/adjusted PAT of the company grew 12.7% / 12% / 29.4% respectively.



Source: Company, NBRR

Adjusted EBIDTA represents adjustments in relation for earn outs payable under the acquisition amounting to Rs.55.42 crore and Rs.28.23 crore respectively in FY24 and Q1FY24 and Rs. 12.4 crore in Q1FY25. Share based payment for Q1FY25 was Rs.85.2 crore. Thus, adjusted EBIDTA margins stood at 25.8% in Q1FY25.

Similarly, Adjusted PAT stands at 11.8% in Q1FY25 after making adjustments for acquisition earnouts, amortization and share based payment awards. Co would be making Rs.135 crore non cash amortization in P&L till 2037.

Profitability metrics for Sagility

Adjusted EBIDTA				
(INR M)	FY2023	FY2024	Q1'FY2024	Q1'FY2025
Revenue from operations	42,184.08	47,535.57	11,160.93	12,233.28
EBIDTA	10,448.64	11,160.37	2,751.44	2,183.74
Adjustments:				
Earnouts under acquisition agreements	-	554.24	282.31	123.76
Share based payment awards	-	-	-	852.15
Adjusted EBIDTA¹	10,448.64	11,714.61	3,033.75	3,159.65
% revenue from operations	24.77%	24.64%	27.18%	25.83%
% growth	-	12.12%	-	4.15%

Adjusted PAT				
(INR M)	FY2023	FY2024	Q1'FY2024	Q1'FY2025
Revenue from operations	42,184.08	47,535.57	11,160.93	12,233.28
PAT	1,435.72	2,282.66	424.99	222.94
Adjustments:				
Earnouts under acquisition agreements (net of tax impact)	-	407.48	207.36	90.77
Amortization of other intangible assets acquired pursuant to business combinations (net of tax impact)	3,120.21	3,205.44	791.76	281.06
Share based payment awards (net of tax impact)	-	-	-	852.15
Adjusted PAT²	4,555.93	5,895.58	1,424.11	1,446.92
% revenue from operations	10.80%	12.40%	12.76%	11.83%
% growth	-	29.40%	-	1.60%

Source: Company and NBRR

Risks and concerns

1. Company derives 100% of its revenues from US markets. Any downturn/slowdown in the US economy will adversely affect Co's financial performance.
2. Any volatility in the currencies can widely affect Company revenue and margins.

Valuation and Recommendation

Sagility holds deep domain expertise and leadership position in the focused payer healthcare market offering comprehensive services as against the other traditional IT players. With growing outsourcing outlook of the traditionally conservative Healthcare industry, Sagility holds a better position to gain traction and gain market share. Shares are available at an adjusted P/E of 24x and EV/EBITDA of 13.3x FY24 earnings which seems reasonable given its highly focused nature of business and thus recommend '**Subscribe**' to the issue.

<i>FY24 Figures</i>	Mastek Ltd	Infosys Ltd	Wipro Ltd	Coforge Ltd	Average	Sagility Limited
Revenue	3,055	1,53,670	89,760	9,179	63,916	4,754
CAGR (FY22-24)	18.3%	22%	6.5%	19.5%	16.46%	13.4%
EBITDA Margin	16.6%	23.8%	7.1%	15.6%	16%	22.9%
Asset Turns (x)	0.8	1.1	0.7	0.8	0.8	0.4
CC Cycle	67	72	47	72	38	56
ROCE (%)	15.5%	37.5%	17.0%	24.4%	23.6%	5.1%
Adj ROE (%)	14.3%	29.7%	14.8%	21.7%	20.1%	9.2%
Debt/Equity	0.3	0.1	0.3	0.3	0.2	0.3
Adj EV/EBITDA	18.0	19.5	46.2	34.7	29.6	13.3
Adj P/E	24.1	27.0	24.4	60.0	33.9	23.8

Financials

Sagility Ltd.

Consolidated Nos

P&L (Rs. Cr)	FY23	FY24	Q1FY25
Net Revenue	4,218.4	4,753.6	1,223.3
% Growth	-	13%	10%
Employee Cost	2,494.2	2,937.6	850.4
% of Revenues	59.1%	61.8%	69.5%
Other expenses	697.0	727.8	179.0
% of Revenues	16.5%	15.3%	14.6%
EBITDA	1,027.2	1,088.1	193.9
EBITDA Margin	24.4%	22.9%	15.9%
Adj EBITDA	1044.86	1171.46	315.97
margin %	24.8%	24.6%	25.8%
Depreciation	644.3	689.2	110.0
Other Income	17.7	27.9	24.4
Interest	214.8	185.1	37.4
Exceptional item	0.0	0.0	0.0
PBT	185.7	241.7	71.0
Tax	42.1	13.4	48.7
Tax rate	23%	6%	69%
PAT	143.6	228.3	22.3
Adj. PAT	455.6	589.6	144.7
margin %	10.8%	12.4%	11.8%
EPS (Post Issue)	1.0	1.3	0.31

Ratios & Others	FY23	FY24	Q1FY25
Debt / Equity	0.4	0.3	0.1
EBITDA Margin (%)	24.4%	22.9%	15.9%
PAT Margin (%)	10.8%	12.4%	11.8%
ROE (%)	7.3%	9.2%	7.6%
ROCE (%)	4.7%	5.1%	5.1%

Turnover Ratios	FY23	FY24	Q1FY25
Debtors Days	92	91	75
Inventory Days	0.0	0.0	0.0
Creditor Days	18	20	19
Asset Turnover (x)	0.4	0.4	0.5

Valuation Ratios	FY23	FY24	Q1FY25
Price/Earnings (x)	30.8	23.8	24.3
EV/EBITDA (x)	15.0	13.3	12.4
EV/Sales (x)	3.7	3.3	3.2
Price/BV (x)	2.3	2.2	1.8

Source: Company Data, NBRR

Balance Sheet (Rs. Cr)	FY23	FY24	Q1FY25
Share Capital	1,919	4,285	4,679
Other Equity	4,288	2,158	2,929
Minority Interest	0	0	0
Networth	6,207	6,443	7,608
Total Loans	2,348	1,934	944
Other non-curr liab.	1,004	1,104	1,051
Trade payable	213	259	253
Other Current Liab	819	924	532
Total Equity & Liab.	10,590	10,664	10,388
Property, Plant and Equipment	295	383	388
CWIP/goodwill	5,460	5,715	5,679
Other Intangible / Right of use	2,852	2,574	2,495
Non Currrent Financial assets	37	48	48
Other non Curr. assets	153	224	198
Inventories	0	0	0
cash and cash equivalents	585	344	376
Investments+loans	0	0	0
Trade receivables(debtor)	1,069	1,181	1,004
Other Current assets	140	194	199
Total Assets	10,590	10,664	10,388

Cash Flow (Rs. Cr)	FY23	FY24	Q1FY25
Profit Before Tax	186	242	71
Provisions & Others	911	869	216
Op. profit before WC	1,097	1,111	287
Change in WC	-70	-11	97
Less: Tax	-170	-126	-14
CF from operations	857	973	370
Purchase/Sale of fixed assets	-144	-183	-27
Sale/Purchase of Investments	2	-301	-374
Interest, dividend and other inc	-16	2	2
Bank deposits (having original ma	29	12	0
Loan (given) / repaid - related part	0	0	0
CF from Investing	-129	-469	-399
Repayment towards Lease Liab	-196	-148	-36
Proceeds from/(repayments of) Lo	-141	-428	342
Proceeds from/(repayments of) Sh	0	-168	-243
interest & div paid	(207)	(7)	(1)
CF from Financing	-545	-751	63
Net Change in cash	183	(247)	34
Cash & Bank at beginning	402	591	342
Cash & Bank at end	585	344	376

Disclosure:

Research Reports that are published by Nirmal Bang Securities Private Limited (hereinafter referred to as “NBSPL”) are for private circulation only. NBSPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001766. NBSPL is also a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited, Metropolitan Stock Exchange of India Limited, Multi Commodity Exchange of India Limited, National Commodity and Derivative Exchange Limited and Indian Commodity Exchange Limited in cash and Equity and Commodities derivatives segments.

NBSPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBSPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBSPL, its associates or analyst or his relatives do not hold any financial interest (Except Investment) in the subject company. NBSPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBSPL or its associates or Analyst or his relatives may or may not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBSPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBSPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company. NBSPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: The research analysts and authors of these reports, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendation.

Disclaimer:

The Research Report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice. NBSPL is not soliciting any action based upon it. Nothing in the research report shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing the research report, we did not take into account the investment objectives, financial situation and particular needs of the reader.

The research report has been prepared for the general use of the clients of NBSPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in the research report in any way. Though disseminated to all the customers simultaneously, not all customers may receive the research report at the same time. NBSPL will not treat recipients as customers by virtue of their receiving the research report. The research report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBSPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBSPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the research report. NBSPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of the research report should rely on their own investigations.

This information is subject to change without any prior notice. NBSPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBSPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of research report, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBSPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of the research report and/or further communication in relation to the research report. Here it may be noted that neither NBSPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in the research report.

Copyright of this document vests exclusively with NBSPL.

Our reports are also available on our website www.nirmalbang.com

Registration granted by SEBI and certification from NISM in no way guarantee performance of NBSPL or provide any assurance of returns to investors.

Nirmal Bang Research (Division of Nirmal Bang Securities Pvt. Ltd.)

B-2, 301/302, Marathon Innova,
Opp. Peninsula Corporate Park
Off. Ganpatrao Kadam Marg
Lower Parel (W), Mumbai-400013
Board No. : 91 22 6723 8000/8001
Fax. : 022 6723 8010